Cord blood stem cells and COVID-19 research

cord blood bank

By clicking on either buttons, you are agreeing to our TOS and disclaimers and will be redirected to an affiliate cord blood banking provider. We might get financial compensation if you sign up with them through our affiliate links. Unlock your special discounts by adding your promo code.

CORD300 in the coupon field to get $300 OFF cord blood and tissue banking. OR cord200 to get $200 OFF if you are getting cord blood banking only.

 “Unlocking Hope: The Promise of Mesenchymal Cell Therapy in COVID-19 and ME/CFS”


In a world gripped by the COVID-19 pandemic, medical researchers have been relentless in their pursuit of treatments and therapies to mitigate the virus’s impact. One remarkable avenue of exploration is mesenchymal cell therapy, and it’s the subject of a groundbreaking webinar hosted by Solve M.E. in collaboration with the Hope Biosciences Research Foundation (HBRF). In this article, we’ll delve into the key takeaways from this enlightening webinar, which has the potential to revolutionize the treatment of COVID-19, Long Covid, and even Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

The Mesenchymal Cell Therapy Revolution

Mesenchymal stem cells (MSCs) have garnered significant attention in recent years due to their regenerative and immunomodulatory properties. These versatile cells can be found in various tissues, such as bone marrow and adipose tissue, and hold immense potential for addressing a wide array of medical conditions.

Solve M.E., a leading organization dedicated to accelerating the discovery of treatments and a cure for ME/CFS, joined forces with HBRF, an institution with a pioneering reputation in FDA-authorized studies concerning mesenchymal cell therapy. Their collaborative webinar showcased promising findings that could have profound implications for COVID-19 prevention and treatment, as well as for the challenging condition known as Long Covid.

Understanding the Studies

HBRF’s groundbreaking work in mesenchymal cell therapy has encompassed three FDA-authorized studies focused on COVID-19 prevention and treatment. Additionally, they have undertaken two studies examining the potential of this therapy in addressing Long Covid.

  1. COVID-19 Prevention and Treatment: Mesenchymal cell therapy offers a multifaceted approach to combatting COVID-19. These cells have the ability to modulate the immune response, reduce inflammation, and promote tissue repair. HBRF’s studies have sought to harness these capabilities effectively.

  2. Long Covid: Long Covid, a condition where individuals continue to experience debilitating symptoms long after recovering from the acute phase of COVID-19, poses a significant challenge to both patients and medical professionals. HBRF’s studies in this area aim to alleviate symptoms and improve the quality of life for those suffering from Long Covid.

The Comprehensive Discussion

During the webinar, Solve M.E. President Oved Amitay and HBRF Founder Donna Chang engaged in an illuminating discussion that touched upon the findings of their studies and the potential for future research in the realm of ME/CFS.

  1. Mesenchymal Cell Therapy Findings: The webinar provided insights into the groundbreaking findings of HBRF’s studies. These studies demonstrated the promise of mesenchymal cell therapy in reducing the severity of COVID-19, hastening recovery, and alleviating Long Covid symptoms. This is particularly significant given the ongoing global impact of the pandemic and the debilitating nature of Long Covid. This might be anotehr reason to do cord blood banking.

  2. Long Covid Study: One of the highlights of the webinar was the announcement of an ongoing Long Covid study. This study holdsthe potential to provide much-needed relief to individuals grappling with Long Covid’s myriad symptoms, which can range from fatigue and cognitive issues to respiratory problems and more.

  3. Future Prospects for ME/CFS Research: The webinar also touched upon the potential for future studies involving mesenchymal cell therapy in addressing ME/CFS. This debilitating condition has long confounded the medical community, and the regenerative potential of MSCs could offer a ray of hope for those affected by ME/CFS.

The Road Ahead

As the world continues to grapple with the COVID-19 pandemic and its lasting effects, the collaboration between Solve M.E. and HBRF offers a beacon of hope. Mesenchymal cell therapy, with its remarkable regenerative and immunomodulatory properties, has the potential to reshape the landscape of COVID-19 treatment and Long Covid management.

Moreover, the prospect of future studies targeting ME/CFS underscores the importance of ongoing research and collaboration in the medical community. With the dedication and innovative spirit showcased in this webinar, there’s a palpable sense that breakthroughs in the understanding andtreatment of ME/CFS may be on the horizon.


The Solve M.E. and HBRF webinar stands as a testament to the power of collaboration, innovation, and hope in the face of unprecedented medical challenges. The mesenchymal cell therapy studies conducted by HBRF, with their focus on COVID-19 prevention and treatment, as well as Long Covid management, offer a glimmer of hope to individuals affected by these conditions.

As we look to the future, the potential for mesenchymal cell therapy to extend its reach to ME/CFS research is an exciting development that holds the promise of transforming the lives of countless individuals living with this enigmatic condition. It is a reminder that in the realm of medical science, discovery knows no bounds, and where there is collaboration, there is the potential for profound change.

Scroll to Top